Data Quantity, Complexity Drives Use of AI in Drug Discovery and Testing
The quantity of data about medicines, diseases, and biology is growing. So too, are the number of companies that employ artificial intelligence in drug discovery. Most of the low-hanging fruit in drug research has already been picked, and the industry is clamoring to make sense of the new data, according to Jeffrey Lu, CEO and co-founder of Engine Biosciences. “There’s only one way to do that—use machines to process the complexity,” Lu said.